Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Heart and Vessels

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF02060240PMID 3722083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Hemodynamic Effects of a New Positive Inotropic Agent, 3,4-Dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), in Conscious and Anesthetized Dogs

  1986cited by this paper
• Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.

  1984cited by this paper
• Effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212) and its solvent sulfolane on isolated heart preparations of the rat, guinea pig, and dog.

  1984influential reference
• Studies on the mechanism of action of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), a new positive inotropic drug. Enzyme activities and Ca2+ transport processes of sarcolemma and intracellular organelles.

  1984cited by this paper
• Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.

  1984influential reference
• Effects of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl] -2(1H)-quinolinone (OPC-8212), a new inotropic agent, on cardiotonic activity and coronary hemodynamics.

  1984cited by this paper
• Pharmacokinetics of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), in the rat, rabbit, beagle dog and rhesus monkey.

  1984cited by this paper
• In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals.

  1984cited by this paper
• Positive inotropic effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1 -piperazinyl]-2(1H)-quinolinone (OPC-8212) and mechanism of action in guinea pig ventricular myocardium.

  1984cited by this paper
• The effect of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), on thin bundles of skinned fibers from cardiac muscle.

  1984cited by this paper
• Evaluating the efficacy of new inotropic agents.

  1984cited by this paper
• Studies on positive inotropic agents. I. Synthesis of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone and related compounds.

  1984cited by this paper
• Electro-mechanical effects of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), a new positive inotropic agent. Isolated adult canine Purkinje strands and ventricular trabeculae.

  1984cited by this paper
• Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.

  1983cited by this paper
• Problems in assessment of new pharmacologic agents for the heart failure patient.

  1981cited by this paper
• Comparative Hemodynamic Effects of Inotropic and Vasodilator Drugs in Severe Heart Failure

  1977cited by this paper

• Pharmacology of SCH00013: a novel Ca2+ sensitizer.

  2006cites this paper
• Subcellular mechanism of the positive inotropic effect of a new quinolinone derivative OPC-8490 on the dog ventricular myocardium

  2005cites this paper
• A new cardiotonic agent, OPC-8212, elevates the myocardial oxygen consumption versus pressure-volume area (PVA) relation in a similar manner to catecholamines and calcium in canine hearts

  2005cites this paper
• Oral OPC-8212 for the treatment of congestive heart failure: Hemodynamic improvement and increased exercise capacity

  2005cites this paper
• Intropic agents in the treatment of heart failure: Despair or hope?

  2004cites this paper
• New positive inotropic agents in the treatment of left ventricular dysfunction.

  2004cites this paper
• Inotropic Agents and Immune Modulation

  2002cites this paper
• A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.

  1999cites this paper
• Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current.

  1997cites this paper
• Implications of Cytokine Inhibition for the Drug Therapy of Heart Failure

  1997cites this paper
• Vesnarinone: a potential cytokine inhibitor.

  1996cites this paper
• Immunomodulation: a new horizon for medical treatment of heart failure.

  1996cites this paper
• Comparison of the Electromechanical Effects of Vesnarinone and Amrinone in Isolated Dog Purkinje Strands and Ventricular Trabeculae

  1996cites this paper
• Immunomodulatory therapy and survival with cardiac disease

  1996cites this paper
• Positive inotropic therapy: an update and new agents.

  1996cites this paper
• Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.

  1995cites this paper
• Vesnarinone: a new inotropic agent for treating congestive heart failure.

  1995cites this paper
• Strategies for pharmacologic modulation of the heart failure phenotype–Modulating the heart failure phenotype

  1995cites this paper
• Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure

  1994cites this paper
• Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia.

  1994cites this paper
• Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.

  1994cites this paper
• The search for the ideal positive inotropic agent.

  1993cites this paper
• Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.

  1993cites this paper
• How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease.

  1993cites this paper
• The development of positive inotropic agents for chronic heart failure: how have we gone astray?

  1993cites this paper
• Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy.

  1991cites this paper
• A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.

  1990cites this paper
• Effects of a new 1,3-thiazole Derivative ZSY-39 on force of contraction and cyclic AMP content in canine ventricular muscle

  1990influential citation
• A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure

  1990cites this paper
• Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes

  1990cites this paper
• Sustained inotropic effects of a new cardiotonic agent. OPC‐8212 in patients with chronic heart failure

  1989cites this paper
• Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.

  1988cites this paper
• OPC-8212 in the treatment of congestive heart failure: Results of a pilot study

  1988cites this paper
• A multicenter study of a new inotropic agent, piperanometozine (opc-8212) in congestive heart failure: Clinical improvement during short-term treatment

  1987cites this paper
• Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure.

  1987cites this paper